Asthma preventive drugs market led by GlaxoSmithKline's Advair

26 November 2012

The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 4.5% through to 2015, driven by the increasing incidence of asthma along with the increased focus on contract manufacturing outsourcing, according to a new report added to the offering of Companiesandmarkets.com

Asthma is a respiratory condition in which the airways become inflamed and constrict, usually in response to one or more environmental triggers. As a serious and potentially fatal condition if left untreated, asthma can be managed by avoiding triggers and with drug therapy.

Over 300 million people suffer from asthma. The global asthma drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 5.7% over the next five years, and to increase from a market value of $15.3 billion recorded in 2012, to hit $20.2 billion by 2017.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical